



## Clinical trial results:

### A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of Asfotase Alfa in up to 10 Severely Affected Patients With for the Treatment of Severely Affected Patients With Infantile Hypophosphatasia (HPP)

#### Summary

EudraCT number	2008-007406-11
Trial protocol	GB
Global end of trial date	21 May 2010

#### Results information

Result version number	v1 (current)
This version publication date	07 August 2016
First version publication date	07 August 2016

#### Trial information

##### Trial identification

Sponsor protocol code	ENB-002-08
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00744042
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Alexion Pharma GmbH
Sponsor organisation address	Giesshübelstrasse 30, Zurich, Switzerland, 8050
Public contact	Alexion Europe SAS, European Clinical Trial Information, +33 147100606, Clinicaltrials.eu@alxn.com
Scientific contact	Alexion Europe SAS, European Clinical Trial Information, +33 147100606, Clinicaltrials.eu@alxn.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000987-PIP01-10
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 November 2012
Is this the analysis of the primary completion data?	Yes
Primary completion date	21 May 2010
Global end of trial reached?	Yes
Global end of trial date	21 May 2010
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

1. To assess the efficacy of asfotase alfa in treating the skeletal manifestations of infantile HPP
2. To determine the safety and tolerability of asfotase alfa given intravenously (IV) in a single dose and subcutaneously (SC) in repeat doses

Protection of trial subjects:

No specific measure

Background therapy: -

Evidence for comparator:

No comparator was used in the study

Actual start date of recruitment	06 October 2008
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety, Ethical reason
Long term follow-up duration	7 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 7
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	United Arab Emirates: 1
Country: Number of subjects enrolled	United Kingdom: 2
Worldwide total number of subjects	11
EEA total number of subjects	2

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	1
Infants and toddlers (28 days-23 months)	7
Children (2-11 years)	3

Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The trial was posted on [clinicaltrials.gov](https://clinicaltrials.gov). Physicians managing the care of infants and young children with a confirmed diagnosis of HPP contacted existing sites or requested assistance with site set up from the sponsor

### Pre-assignment

Screening details:

All screened patients met eligibility criteria and were enrolled in the study.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Asfotase Alfa
-----------	---------------

Arm description:

All enrolled patients receive a single IV (intravenous) dose of Asfotase Alfa of 2 mg/kg followed by 7 days of observation. Following an assessment of safety data by an independent Data Safety Monitoring Board (DSMB), patients begin thrice weekly SC (subcutaneous) injections of Asfotase Alfa at a dose of 1 mg/kg for the remaining 23 weeks of the study.

Arm type	Experimental
Investigational medicinal product name	Asfotase alfa
Investigational medicinal product code	Asfotase alfa
Other name	ENB-0040
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use, Intravenous use

Dosage and administration details:

All enrolled patients receive a single IV (intravenous) dose of Asfotase Alfa of 2 mg/kg followed by 7 days of observation. Following an assessment of safety data by an independent Data Safety Monitoring Board (DSMB), patients begin thrice weekly SC (subcutaneous) injections of Asfotase Alfa at a dose of 1 mg/kg for the remaining 23 weeks of the study.

Number of subjects in period 1	Asfotase Alfa
Started	11
Completed	10
Not completed	1
Consent withdrawn by subject	1

## Baseline characteristics

### Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	11	11	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	1	1	
Infants and toddlers (28 days-23 months)	7	7	
Children (2-11 years)	3	3	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	1.11		
standard deviation	± 1.13	-	
Gender categorical			
Units: Subjects			
Female	7	7	
Male	4	4	

## End points

### End points reporting groups

Reporting group title	Asfotase Alfa
Reporting group description: All enrolled patients receive a single IV (intravenous) dose of Asfotase Alfa of 2 mg/kg followed by 7 days of observation. Following an assessment of safety data by an independent Data Safety Monitoring Board (DSMB), patients begin thrice weekly SC (subcutaneous) injections of Asfotase Alfa at a dose of 1 mg/kg for the remaining 23 weeks of the study.	

### Primary: Change in Rickets Severity From Baseline to Week 24, Based on Assessment of Skeletal Radiographs Using Radiologic Global Impression of Change (RGI-C)

End point title	Change in Rickets Severity From Baseline to Week 24, Based on Assessment of Skeletal Radiographs Using Radiologic Global Impression of Change (RGI-C) <sup>[1]</sup>
-----------------	--

End point description:

A 7-point RGI-C (Radiographic Global Impression of Change) score was used to rate change in rickets severity. Scores ranged from -3 (severe worsening of rickets) to +3 (complete healing of rickets). Only those patients with a minimum score of +2 indicating substantial healing of rickets) were considered "responders". Three pediatric radiologists not affiliated with the conduct of the study performed the ratings. Average scores were derived for each patient at each assessment.

End point type	Primary
----------------	---------

End point timeframe:

24 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The system EudraCT does not allow entering for statistical analysis for single arm studies. Thus, the analysis was removed in order to resolve the IT 'error'.

<b>End point values</b>	Asfotase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	11 <sup>[2]</sup>			
Units: Units on a scale				
median (full range (min-max))	2 (0 to 2.33)			

Notes:

[2] - ITT (intention to treat)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum Serum Concentration of Asfotase Alfa (Cmax)

End point title	Maximum Serum Concentration of Asfotase Alfa (Cmax)
-----------------	---

End point description:

Maximum serum concentration observed during intensive PK sampling interval.

Study Week 1 Intravenous Dose (2 mg/kg Single Dose): Participants received intravenous (IV) asfotase alfa (2 mg/kg single dose) on Day 1. PK samples drawn pre-dose to 168 hours post-dose.

Study Week 2 Subcutaneous Dose (1 mg/kg 3x/Week): Participants received subcutaneous (SC) asfotase alfa starting on Day 8 (Week 2) (1 mg/kg 3x/week). PK samples drawn pre-dose to 48 hours post-dose for PK analysis following single SC dose.

Study Week 3 Subcutaneous Dose (1mg/kg 3x/Week): Participants received subcutaneous (SC) asfotase alfa starting on Day 8 (Week 2) (1 mg/kg 3x/week). PK samples drawn pre-dose to 48 hours post-dose for PK analysis following multiple SC doses.

End point type	Secondary
End point timeframe:	
Study Week 1 (0 to 168 hours post-dose). Study Week 2 and Study Week 3 (0 to 48 hours post-dose)	

End point values	Asfotase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	11 <sup>[3]</sup>			
Units: U/L				
arithmetic mean (standard deviation)				
Study week 1, IV 2 mg/kg single dose	2230 (± 1100)			
Study week 2, SC 1 mg/kg three times/week	376 (± 226)			
Study week 3, SC 1 mg/kg three times/week	897 (± 491)			

Notes:

[3] - week 1 - 6 participants analysed  
week 2 - 7 participants analysed  
week 3 - 7 participants analysed

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time at Maximum Serum Concentration of Asfotase Alfa (Tmax)

End point title	Time at Maximum Serum Concentration of Asfotase Alfa (Tmax)
-----------------	---

End point description:

Time at maximum serum concentration observed during intensive PK sampling interval.

Study Week 1 Intravenous Dose (2 mg/kg Single Dose): Participants received intravenous (IV) asfotase alfa (2 mg/kg single dose) on Day 1. PK samples drawn pre-dose to 168 hours post-dose.

Study Week 2 Subcutaneous Dose (1 mg/kg 3x/Week): Participants received subcutaneous (SC) asfotase alfa starting on Day 8 (Week 2) (1 mg/kg 3x/week). PK samples drawn pre-dose to 48 hours post-dose for PK analysis following single SC dose.

Study Week 3 Subcutaneous Dose (1mg/kg 3x/Week): Participants received subcutaneous (SC) asfotase alfa starting on Day 8 (Week 2) (1 mg/kg 3x/week). PK samples drawn pre-dose to 48 hours post-dose for PK analysis following multiple SC doses.

End point type	Secondary
End point timeframe:	
Study Week 1 (0 to 168 hours post-dose). Study Week 2 and Study Week 3 (0 to 48 hours post-dose).	

End point values	Asfotase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	11 <sup>[4]</sup>			
Units: hour				
arithmetic mean (standard deviation)				
Study week 1 (IV, single dose 2 mg/kg)	4.3 (± 4.3)			

Study week 2 (SC, 1 mg/kg 3 times/week)	29.7 (± 13.2)			
Study week 3 (SC, 1 mg/kg 3 times/week)	12 (± 7.7)			

Notes:

[4] - week 1 - 6 participants analysed  
week 2 - 7 participants analysed  
week 3 - 7 participants analysed

## Statistical analyses

No statistical analyses for this end point

## Secondary: Area Under Serum Concentration-time Curve to Last Measurable Concentration of Asfotase Alfa (AUCt)

End point title	Area Under Serum Concentration-time Curve to Last Measurable Concentration of Asfotase Alfa (AUCt)
-----------------	--

End point description:

Area under serum concentration-time curve to last measurable concentration during intensive PK sampling interval.

Study Week 1 Intravenous Dose (2mg/kg Single Dose): Participants received intravenous (IV) asfotase alfa (2mg/mg single dose) on Day 1. PK samples drawn pre-dose to 168 hours post-dose.

Study Week 2 Subcutaneous Dose: (1mg/kg 3x/Week) Participants received subcutaneous (SC) asfotase alfa starting on Day 8 (Week 2) (1 mg/kg 3x/week). PK samples drawn pre-dose to 48 hours post-dose for PK analysis following single SC dose.

Study Week 3 Subcutaneous Dose: (1mg/kg 3x/Week) Participants received subcutaneous (SC) asfotase alfa starting on Day 8 (Week 2) (1 mg/kg 3x/week). PK samples drawn pre-dose to 48 hours post-dose for PK analysis following multiple SC doses.

End point type	Secondary
----------------	-----------

End point timeframe:

Study Week 1 (0 to 168 hours post-dose). Study Week 2 and Study Week 3 (0 to 48 hours post-dose).

End point values	Asfotase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	11 <sup>[5]</sup>			
Units: h*U/L				
arithmetic mean (standard deviation)				
Study week 1 (IV, 2 mg/kg single dose)	79800 (± 21700)			
Study week 2 (SC, 1 mg/kg 3 times/week)	14799 (± 9730)			
Study week 3 (SC, 1 mg/kg 3 times/week)	33700 (± 19700)			

Notes:

[5] - week 1 - 6 participants analysed  
week 2 - 7 participants analysed  
week 3 - 7 participants analysed

## Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

6 months

Adverse event reporting additional description:

All patients who received any asfotase alfa treatment, regardless of whether they were lost to follow-up or dropped out of the trial.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13
--------------------	----

### Reporting groups

Reporting group title	Asfotase Alfa
-----------------------	---------------

Reporting group description:

All enrolled patients receive a single IV (intravenous) dose of Asfotase Alfa of 2 mg/kg followed by 7 days of observation. Following an assessment of safety data by an independent Data Safety Monitoring Board (DSMB), patients begin thrice weekly SC (subcutaneous) injections of Asfotase Alfa at a dose of 1 mg/kg for the remaining 23 weeks of the study.

Serious adverse events	Asfotase Alfa		
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 11 (63.64%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Investigations			
Oxygen saturation decreased			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Collapse of lung			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
convulsion			
alternative assessment type: Non-systematic			

subjects affected / exposed	2 / 11 (18.18%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Intracranial pressure increased			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Medical device related complication	Additional description: Catheter related complication		
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Respiratory distress			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypoxia			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Obstructive airway disorder			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Restrictive pulmonary disease			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory depression			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Craniosynostosis			
alternative assessment type: Non-systematic			
subjects affected / exposed	3 / 11 (27.27%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Pneumonia			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis salmonella			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection viral			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 11 (9.09%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia respiratory syncytial viral alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory syncytial virus bronchiolitis alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sepsis alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
H1N1 influenza1 Influenza alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection alternative assessment type: Non-systematic				

subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Asfotase Alfa		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 11 (100.00%)		
Vascular disorders			
Flushing			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Secondary hypertension			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Surgical and medical procedures			
Central venous catheter removal			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
General disorders and administration site conditions			
Pyrexia			
alternative assessment type: Non-systematic			
subjects affected / exposed	5 / 11 (45.45%)		
occurrences (all)	5		
Irritability			
alternative assessment type: Non-systematic			
subjects affected / exposed	4 / 11 (36.36%)		
occurrences (all)	4		
Injection site erythema			

alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	15		
Catheter site erythema			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Catheter site rash			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Thrombosis in device			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Chills			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Drug withdrawal syndrome			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Hernia			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Injection site haematoma			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	4		
Injection site induration			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Injection site nodule			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Injection site pain			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Injection site papule			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Injection site pruritus			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Injection site rash			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Injection site warmth			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Oedema			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Pain			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		

Immune system disorders Seasonal allergy alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Respiratory, thoracic and mediastinal disorders Cough alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Nasal ulcer alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Tachypnoea alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Pharyngeal erythema alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Respiratory depression alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 2  1 / 11 (9.09%) 1  1 / 11 (9.09%) 1  1 / 11 (9.09%) 1  1 / 11 (9.09%) 1		
Psychiatric disorders Drug dependence alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Agitation alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 3  2 / 11 (18.18%) 2		



<p>Breath holding</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p>		
<p>Anxiety</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p>		
<p>Investigations</p> <p>Haemoglobin decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Urine calcium/creatinine ratio increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Culture positive</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 11 (36.36%)</p> <p>9</p> <p>1 / 11 (9.09%)</p> <p>1</p> <p>1 / 11 (9.09%)</p> <p>1</p>		
<p>Injury, poisoning and procedural complications</p> <p>Fall</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Procedural pain</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Procedural site reaction</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Radius fracture</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Wound</p>	<p>2 / 11 (18.18%)</p> <p>2</p> <p>1 / 11 (9.09%)</p> <p>1</p> <p>1 / 11 (9.09%)</p> <p>1</p> <p>1 / 11 (9.09%)</p> <p>1</p>		

<p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p>		
<p>Feeding tube complication</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p>		
<p>Congenital, familial and genetic disorders</p> <p>Congenital bowing of long bones</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Craniosynostosis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Atrial septal defect</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p> <p>1 / 11 (9.09%)</p> <p>1</p> <p>1 / 11 (9.09%)</p> <p>1</p>		
<p>Cardiac disorders</p> <p>Bradycardia</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p>		
<p>Nervous system disorders</p> <p>Headache</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>2</p>		
<p>Blood and lymphatic system disorders</p> <p>Anemia</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Tachycardia</p>	<p>2 / 11 (18.18%)</p> <p>2</p>		

alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2		
Eye disorders Ocular hyperaemia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Gastrointestinal disorders Vomiting alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) Constipation alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) Flatulence alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) Gastrooesophageal reflux disease alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) Gingival erythema alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) Nausea alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) Stomatitis alternative assessment type: Non-systematic	3 / 11 (27.27%) 3 4 / 11 (36.36%) 4 2 / 11 (18.18%) 2 1 / 11 (9.09%) 2 1 / 11 (9.09%) 1 1 / 11 (9.09%) 1		

subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Teething			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Hypothermia			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Diarrhea			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Gastritis			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Dermatitis diaper			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Erythema			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Excessive granulation tissue			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Hyperhidrosis			
alternative assessment type: Non-systematic			

<p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p> <p>Increased tendency to bruise</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>6</p> <p>Piloerection</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p> <p>Pruritus</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Renal and urinary disorders</p> <p>Nephrolithiasis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Musculoskeletal and connective tissue disorders</p> <p>Bone pain</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p> <p>Myalgia</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p> <p>Pain in extremity</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>2</p>			
<p>Infections and infestations</p> <p>Pneumonia</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p>			

Nasopharyngitis				
alternative assessment type: Non-systematic				
subjects affected / exposed	2 / 11 (18.18%)			
occurrences (all)	4			
Otitis media				
alternative assessment type: Non-systematic				
subjects affected / exposed	2 / 11 (18.18%)			
occurrences (all)	2			
Sinusitis				
alternative assessment type: Non-systematic				
subjects affected / exposed	2 / 11 (18.18%)			
occurrences (all)	3			
Upper respiratory tract infection				
alternative assessment type: Non-systematic				
subjects affected / exposed	2 / 11 (18.18%)			
occurrences (all)	4			
Bacterial tracheitis				
alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Bronchiolitis				
alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Device related infection				
alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Exanthema subitum				
alternative assessment type: Non-systematic				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Gastroenteritis				
alternative assessment type: Non-systematic				

subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Gastroenteritis rotavirus			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Pneumonia staphylococcal			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Skin candida			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Tracheitis			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Viral infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Pneumonia respiratory syncytial viral			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Hypocalcaemia			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	2		
Food intolerance			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Hyperphosphataemia			

subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Hypercalcaemia			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Metabolic acidosis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 September 2008	Modification of the inclusion criteria and in the conduct of the trial
20 November 2008	Modification in the PK assessment schedule and in the dosing regimen
12 June 2009	Modification in the dosing schedule and in the conduct of the trial

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/18086009>

<http://www.ncbi.nlm.nih.gov/pubmed/18318644>

<http://www.ncbi.nlm.nih.gov/pubmed/22397652>